



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/670,006	09/24/2003	Randal Meyer	P06095US01	6245
22885	7590 07/14/2005		EXAMINER	
MCKEE, VC 801 GRAND	ORHEES & SEASE,	LILLING, HERBERT J		
SUITE 3200			ART UNIT	PAPER NUMBER
DES MOINES, IA 50309-2721			1651	· · · · · · · · · · · · · · · · · · ·

DATE MAILED: 07/14/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Υ.	17	
	Application No.	Applicant(s)
	10/670,006	MEYER, RANDAL
Office Action Summary	Examiner	Art Unit
	HERBERT J. LILLING	1651
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).
Status		
 1) Responsive to communication(s) filed on 24 Section 24 Section 24 Section 24 Section 25 This action is FINAL. 2b) This 3) Since this application is in condition for allower closed in accordance with the practice under Exercise 24 Section 24 Section 25 Section 25 Section 26 Sec	action is non-final. nce except for formal matters, pro	
Disposition of Claims		
 4) ☐ Claim(s) 1-11 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 1-11 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or 	vn from consideration.	
Application Papers		·
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Examine	epted or b) objected to by the Identified or b) objected to by the Identified or by the Ident	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		. ,
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati ity documents have been receive ı (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)	
Paper No(s)/Mail Date September 24, 2003.		atent Application (PTO-152)

Application/Control Number: 10/670,006

Page 2

Art Unit: 1651

1. Receipt is acknowledged of the prior art information disclosure statement filed September 24, 2003.

- 2. Claims 1-11 are pending in this application, which is a CIP of Ser Number 10/424,517, filed April 28, 2003.
- 3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-11 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention with respect to the following:

- a. The statement in claim 1 that "the PLD enzyme is of the genus *Streptomyces*" which statement appears to be in error.
 - b. There is missing information pertaining to the strain.
 - 4. Claims 1-11 are rejected under the judicially created doctrine of double patenting over claims of U. S. Patent No 6,878,532 since the claims, if allowed, would improperly extend the "right to exclude" already granted in the patent.

The subject matter claimed in the instant application is fully disclosed in the patent and is covered by the patent since the patent and the application are claiming common subject matter.

Application/Control Number: 10/670,006

Art Unit: 1651

Furthermore, there is no apparent reason why applicant was prevented from presenting claims corresponding to those of the instant application during prosecution of the application, which matured into a patent. See *In re Schneller*, 397 F.2d 350, 158 USPQ 210 (CCPA 1968). See also MPEP § 804.

5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Application/Control Number: 10/670,006 Page 4

Art Unit: 1651

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-11 are rejected fewer than 35 U.S.C. 102(b) as anticipated by Kokusho et al, U.S. 4,783,402 which reference teaches the production of exchanging a base for production of phospholipids which includes phosphatidylserine formed by a reaction of a PLD enzyme in the presence of an alcohol in a solvent.

Or, in the alternative:

Claims 1-11 are rejected under 35 U.S.C. 103(a) as obvious over Kokusho et al, U.S. 4,783,402 further in view of Yamane et al, U.S. 6,660,504 or Kirschner et al U.S. 6 The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
 - 3. Resolving the level of ordinary skill in the pertinent ad.
 - 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Kokusho et al does not teach an enzyme obtained from Streptomyces but Yamane et al or Kirschner teaches PLD enzymes which enzymes would have been prima facie obvious to substitute for those of Kokusho et al absent unexpected or unobvious process steps for the method of combining a phospholipids with a hydroxyl containing compound based on the broad disclosure of the reference.

If there are any differences with respect to any other processing conditions, these differences would have been prima facie obvious in view of the broad disclosure of Kokusho et al to produce the phosphatidyl product absent unexpected and unobvious process steps.

7. No claim is allowed.

- 8. The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.
- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to **Examiner Lilling** whose telephone number is 571-272-0918 and Fax Number is (703) 872-9306 or SPE Michael Wityshyn whose telephone number is 571-272-0926. Examiner can be reached Monday-Thursday from about 5:30 A.M. to about 3:00 P.M. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Application/Control Number: 10/670,006

Art Unit: 1651

Page 6

Information regarding the status of an application may be obtained from the Patent Application information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For information about the PAIR more system, see http://portal.uspto.gov/external/portal/pair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

H.J.Lilling: HJL (571) 272-0918 Art Unit <u>1651</u> July 13, 2005

> Dr. Herbert J. Lilling Primary Examiner

Group 1600 Art Unit 1651